Financials data is unavailable for this security.
View more
Year on year Adaptive Biotechnologies Corp 's revenues fell -8.11% from 185.31m to 170.28m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 200.19m to a larger loss of 225.25m.
Gross margin | 58.46% |
---|---|
Net profit margin | -110.19% |
Operating margin | -112.69% |
Return on assets | -30.61% |
---|---|
Return on equity | -66.69% |
Return on investment | -35.66% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Adaptive Biotechnologies Corp fell by 24.43m. However, Cash Flow from Investing totalled 129.65m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 156.32m for operations while cash generated from financing totalled 2.25m.
Cash flow per share | -1.20 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.52 |
---|---|
Tangible book value per share | 0.6841 |
More ▼
Balance sheet in USDView more
Current ratio | 3.52 |
---|---|
Quick ratio | 3.38 |
Total debt/total equity | 0.593 |
---|---|
Total debt/total capital | 0.3725 |
More ▼